Product Program year 2020 Source: CMS Open Payments

Breztri Aerosphere

Drug Respiratory

NDC 0310-4616-12

Open in the dashboard

General payments

$1,410,351

24,934 payments

Research payments

$296,903

7 payments

Through program year 2020, $1,410,351 in general payments and $296,903 in research payments were reported against Breztri Aerosphere (Respiratory).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2020 General $1,410,351 24,934
2020 Research $296,903 7

Breakdown

Who paid General payments · program year 2020
  1. AstraZeneca Pharmaceuticals LP $1,406,757 24,928 payments
  2. AstraZeneca UK Limited $3,594 6 payments
Top recipients General payments · program year 2020
  1. Michael Wert Pulmonary Disease · Greensboro, NC $29,170 2% · 39 payments
  2. David Mares Pulmonary Disease · Anderson, IN $26,880 2% · 26 payments
  3. Demondes Haynes Pulmonary Disease · Jackson, MS $21,535 2% · 28 payments
  4. Junaid Malik Pulmonary Disease · Orlando, FL $20,872 1% · 33 payments
  5. Bartolome Celli Pulmonary Disease · Boston, MA $19,222 1% · 12 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Pulmonary Disease Internal Medicine $819,791 59% · 2,154 practitioners
  2. Family Medicine $265,892 19% · 5,838 practitioners
  3. Internal Medicine $185,374 13% · 3,958 practitioners
  4. Allergy & Immunology $35,141 3% · 670 practitioners
  5. Critical Care Medicine Internal Medicine $31,448 2% · 214 practitioners

The top 5 of 68 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. Florida $127,765 9% · 1,049 recipients
  2. California $107,441 8% · 1,036 recipients
  3. Texas $102,093 7% · 1,263 recipients
  4. New York $95,896 7% · 995 recipients
  5. Pennsylvania $81,181 6% · 616 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,165,471

Prescriptions dispensed, refills included

Drug cost

$912,446,611

Paid at the pharmacy, in all

Prescribers

29,313

With 11 or more claims of it

Medicare Part D drugs matched to BREZTRI AEROSPHERE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Same name 29,313 1,165,471 $912,446,611

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jorge Sanchez-Masiques Pulmonary Disease FL 1,712 $1,106,669 None on record
Humam Farah Pulmonary Disease MO 1,220 $923,560 None on record
Huan Le Pulmonary Disease CA 1,159 $706,575 None on record
Hoang Le Pulmonary Disease CA 1,025 $684,639 None on record
Yoel Brito Pulmonary Disease FL 1,007 $685,752 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
24,934 general · 7 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record